Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Almirall

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Almirall's 2013 sales performance.

Novartis' Ultibro tops Seretide in comparative COPD trial

Novartis' Ultibro tops Seretide in comparative COPD trial With Seretide already succumbing to generic competition and other entrants from AstraZeneca and Forest Laboratories/Almirall also coming through the pipeline, the market is expected to fragment with the new generation

Deal Watch table for July 2014

Deal Watch table for July 2014 2, 700. Almirall/ AstraZeneca. Asset acquisition. Respiratory business including various respiratory assets and device capabilities.

Pharma deals during July 2014

Pharma deals during July 2014 AZ will also acquire Almirall Sofotec, Almirall's inhalation device business which includes Genuair, its novel multi-dose dry powder inhalation (DPI) device. ... Almirall will receive $875m upfront and up to $1.22bn in development, launch, and

FDA approves Boehringer COPD spray Striverdi Respimat

FDA approves Boehringer COPD spray Striverdi Respimat Meanwhile Almirall, whose respiratory franchise is to be bought by AstraZeneca in a $2bn deal, has its own COPD combination - aclidinium bromide/formoterol candidate - in phase III with Forest Labs.

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio Commenting on the Almirall deal Soriot said: “We will benefit from immediate and growing product revenues which we anticipate will be rapidly accretive to earnings. ... Almirall president Jorge Gallardo said the AZ deal would “better develop our

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics